source
- Verastem makes its stand as a RevMed competitor in pancreatic cancerVerastem Oncology had a big Wednesday morning: It announced new data amid a tense competition for the next-wave KRAS agents, as well as a $250 million raise and the departure of its CEO. The Massac…
- Roche signs $1.2 bn obesity partnership with China's Rona Therapeutics, paying up to $100 m upfrontRoche announced its seventh China deal this year, partnering with RNA‑interference specialist Rona Therapeutics to target obesity. The collaboration licenses an ALK7 inhibition asset and includes…